Believe it or not: how much can we rely on published data on potential drug targets?

  title={Believe it or not: how much can we rely on published data on potential drug targets?},
  author={Florian Prinz and Thomas Schlange and Khusru Asadullah},
  journal={Nature Reviews Drug Discovery},
1. This indicates the limitations of the predictivity of disease models and also that the validity of the targets being investigated is frequently questionable, which is a crucial issue to address if success rates in clinical trials are to be improved. Candidate drug targets in industry are derived from various sources, including inhouse target identification campaigns, inlicensing and public sourcing, in particular based on reports published in the literature and presented at conferences… 
Why is publication of negative clinical trial data important?
The impact of reducing failure in clinical trials should be greater than reducing failure at all points along the drug discovery and development process, as this is where the most spend occurs.
Target Selection and Validation in Drug Discovery
This chapter examines likely root causes and the vigorous response in many areas of drug discovery, including improved target identification and validation technologies, network pharmacology, greater collaborative ways of working and use of biomarkers and patient stratification.
Public–Private Partnerships in Lead Discovery: Overview and Case Studies
The value of public–private partnership approaches will be discussed, using examples from the Innovative Medicines Initiative (IMI), which describe consortia approaches to develop tools and processes for improving target identification and validation, as well as lead identification and optimization.
Improving target assessment in biomedical research: the GOT-IT recommendations
Academic research plays a key role in identifying new drug targets, including understanding target biology and links between targets and disease states. To lead to new drugs, however, research must
Minimizing bias in target selection by exploiting multidisciplinary Big Data and the protein interactome.
The case for minimizing bias in target selection by exploiting multidisciplinary Big Data and assessing targets based on their biological, chemical and physical properties, as well as their role in the cellular protein interactome is argued.
“Omics”-Informed Drug and Biomarker Discovery: Opportunities, Challenges and Future Perspectives
The coming of age of Omics-based applications makes available a formidable technological resource to further expand the authors' knowledge of the complexities of human disease, and together could potentially enable a much-needed systems biology perspective of the perturbations underlying disease processes.
Opportunities and challenges in phenotypic drug discovery: an industry perspective
This article focuses on the lessons learned by researchers engaged in PDD in the pharmaceutical industry and considers the impact of 'omics' knowledge in defining a cellular disease phenotype in the era of precision medicine, introducing the concept of a chain of translatability.
Levelling the Translational Gap for Animal to Human Efficacy Data
Three contributions to tackle the evaluation of the predictive value of animal models of disease themselves are discussed, including the Framework to Identify Models of Disease (FIMD), the first step to standardise the assessment, validation and comparison of disease models.
Chemical Strategies for Evaluating New Drug Targets
It is shown that a large proportion of biomedical R&D focuses on only a small fraction of the genome despite the promised revolution in medicine following sequencing of the entire human genome, and that selecting genetically supported targets can double the success rate in clinical development.


Trial watch: Phase II failures: 2008–2010
Well-conducted Phase II clinical trials provide the data required to determine whether there is a case to be made, both scientifically and commercially, for progressing a drug candidate into Phase III trials, but results are lower than at any other phase of development.
Why Most Published Research Findings Are False
Simulations show that for most study designs and settings, it is more likely for a research claim to be false than true.
What happens to the manuscripts that have not been accepted for publication in Occupational and Environmental Medicine?
  • B. Nemery
  • Medicine, Psychology
    Occupational and environmental medicine
  • 2001
More than half the articles rejected by OEM found their way into the scientific literature covered by Medline, comparable with the few available data from other journals.
What errors do peer reviewers detect, and does training improve their ability to detect them?
Abstract Objective To analyse data from a trial and report the frequencies with which major and minor errors are detected at a general medical journal, the types of errors missed and the impact of
Factors Affecting Reproducibility between Genome-Scale siRNA-Based Screens
It is proposed that the entire data set derived from functional genome-scale screens, especially if publicly funded, should be made available as is done with data derived from gene expression and genome-wide association studies.
Fate of Submitted Manuscripts Rejected from the American Journal of Neuroradiology: Outcomes and Commentary
Findings should give hope to authors receiving a rejection from AJNR, because greater than 50% of articles rejected from AJ NR are subsequently published within 2–3 years, irrespective of publication type, into high-quality journals.
Hedging against academic risk
The potential for not being able to reproduce academic data is a disincentive to early stage investors, so some VC firms are hiring CROs to independently validate academic science prior to putting up serious money.
2008 to 2010
outcomes and commentary
  • Am. J. Neuroradiol. 28, 1430–1434
  • 2007
Lies , damned lies , and medical science
  • 2010